Winton Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Winton Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,882	Closed	-$989K	–	1189
2023 Q1	$989K	Buy	10,882 +1,865	+21%	+$109K	0.06%	449
2022 Q4	$343K	Buy	9,017 +331	+4%	+$11.4K	0.02%	754
2022 Q3	$218K	Sell	8,686 -1,132	-12%	-$31.4K	0.01%	863
2022 Q2	$298K	Sell	9,818 -6,510	-40%	-$194K	0.02%	805
2022 Q1	$535K	Buy	+16,328	New	+$485K	0.03%	662
2021 Q3	–	Sell	-2,733	Closed	-$387K	–	1514
2021 Q2	$387K	Sell	2,733 -2,404	-47%	-$271K	0.02%	1057
2021 Q1	$512K	Buy	5,137 +742	+17%	+$86.5K	0.03%	876
2020 Q4	$543K	Sell	4,395 -8,526	-66%	-$1.12M	0.04%	752
2020 Q3	$1.26M	Buy	+12,921	New	+$1.61M	0.04%	714
2019 Q2	–	Sell	-2,386	Closed	-$204K	–	1319
2019 Q1	$204K	Buy	+2,386	New	+$198K	﹤0.01%	964

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winton Group's RETA Position: Q2 2023 in Review

Winton Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 10,882 shares — an estimated $989K sold.

Winton Group first reported a position in RETA in Q1 2019 and held it in 10 quarters. The position peaked at $1.26M in Q3 2020. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Winton Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Winton Group sold 10,882 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $989K.
Winton Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 10 quarters.
Winton Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.26M in Q3 2020.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.